Citron Research: Questcor in Cover-Up Mode – ValueWalk Premium
questcor logo

Citron Research: Questcor in Cover-Up Mode

QuestcorOver the coming months, Citron Research will release a series of articles on Questcor Pharmaceuticals Inc (NASDAQ:QCOR) intended to shed light on probable issues of interest to the multi-pronged investigation underway by multiple regulatory agencies into numerous aspects of Questcor’s business strategy that political correct-speak would deem “legally challenged”.  These articles will dig deeper into topics such as:

  • The Chronic Disease Fund, and the role it plays in contributing to Questcor Pharmaceuticals Inc (NASDAQ:QCOR)’s revenues
  • Medicare billing (it is very dangerous to participate in a scheme to defraud the Federal Government)
  • Insurance reimbursement coding for Acthar

Meanwhile, today’s question is whether Questcor Pharmaceuticals Inc (NASDAQ:QCOR)’s Synacthen acquisition is anti-competitive.  The points raised in Citron’s article last week are relevant to the FTC’s inquiry, demonstrating Questcor’s intent to suppress competition by acquiring Synacthen is exposed by their own sell-side analysts.

We are sure that Questcor Pharmaceuticals Inc (NASDAQ:QCOR) will now try to posture to the FTC that Synacthen is a completely different drug, arguing that while it has similarities, it cannot be regarded as a replacement for HP Acthar Gel.  This piece of evidence presented below is for the FTC, so shareholders please cover your eyes.

See full PDF here.

Questcor Update Final by ValueWalk.com

LEAVE A COMMENT


X
Saved Articles
X
TextTExtLInkTextTExtLInk

The Life and Career of Charlie Munger

Charlie is more than just Warren Buffett’s friend and Berkshire Hathaway’s Vice Chairman – Buffett has actually credited him with redefining how he looks at investing. Now you can learn from Charlie firsthand via this incredible ebook and over a dozen other famous investor studies by signing up below:

  • Learn from the best and forever change your investing perspective
  • One incredible tidbit of knowledge after another in the page-turning masterpiece of a book
  • Discover the secrets to Charlie’s success and how to apply it to your investing
Never Miss A Story!
Subscribe to ValueWalk Newsletter. We respect your privacy.

What’s missing today for many investors is real, straightforward advice.

Especially when it comes to Value Investing and Hedge Funds. 💵

That’s what makes ValueWalk Premium different. Some would say we’re “unusual.”

Our subscribers look forward to clear, easy-to-understand information they can act on.

Sign up for  today for only a few dollars a day and get a 3 day no obligation trial with a targeted 20% discount coupon code.

Cancel anytime during trial and you are never charged.

Limited time offer: For first 50 subscribers

0